<DOC>
	<DOC>NCT00201955</DOC>
	<brief_summary>The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).</brief_summary>
	<brief_title>Study of Rebamipide Eye Drops to Treat Dry Eye</brief_title>
	<detailed_description>There is a need for effective therapy for dry eye that treats the underlying cause of the syndrome. The goal of this study is to assess the impact of rebamipide on dry eye symptoms.</detailed_description>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>must have symptoms of dry eye for a minimum of 6 months must be able to sign and date an informed consent presence of anterior segment disease glaucoma or ocular hypertension using Restasis use of topically instilled ocular medications during study use of contact lenses history of ocular surgery within 12 months females who are pregnant, breast feeding, or childbearing potential and not willing to remain abstinent or use contraception presence of StevensJohnson syndrome any anticipated change in medication throughout study concurrent involvement in another study or previous receipt of this drug cannot be safely be weaned off of ocular medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>dry eye</keyword>
	<keyword>keratoconjunctivitis sicca</keyword>
</DOC>